ES2616255T3 - Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas - Google Patents

Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas Download PDF

Info

Publication number
ES2616255T3
ES2616255T3 ES09739460.5T ES09739460T ES2616255T3 ES 2616255 T3 ES2616255 T3 ES 2616255T3 ES 09739460 T ES09739460 T ES 09739460T ES 2616255 T3 ES2616255 T3 ES 2616255T3
Authority
ES
Spain
Prior art keywords
heterocycloalkyl
heterocycloalkenyl
heteroaryl
aryl
cycloalkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09739460.5T
Other languages
English (en)
Spanish (es)
Inventor
Hsing-Pang Hsieh
Mohane Selvaraj Coumar
Tsu-An Hsu
Su-Ying Wu
Yu-Sheng Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Application granted granted Critical
Publication of ES2616255T3 publication Critical patent/ES2616255T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES09739460.5T 2008-04-30 2009-04-22 Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas Active ES2616255T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49063 1979-06-18
US4906308P 2008-04-30 2008-04-30
PCT/US2009/041382 WO2009134658A2 (en) 2008-04-30 2009-04-22 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2616255T3 true ES2616255T3 (es) 2017-06-12

Family

ID=41255689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09739460.5T Active ES2616255T3 (es) 2008-04-30 2009-04-22 Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas

Country Status (12)

Country Link
US (1) US8138194B2 (enExample)
EP (1) EP2276346B1 (enExample)
JP (1) JP5502072B2 (enExample)
KR (1) KR101667822B1 (enExample)
CN (1) CN102014627B (enExample)
AU (1) AU2009241469B2 (enExample)
CA (1) CA2722220C (enExample)
DK (1) DK2276346T3 (enExample)
ES (1) ES2616255T3 (enExample)
PL (1) PL2276346T3 (enExample)
TW (1) TWI363627B (enExample)
WO (1) WO2009134658A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012130929A (ru) * 2009-12-23 2014-01-27 Байокрист Фармасьютикалз, Инк. Гетероциклические соединения в качестве ингибиторов янус-киназы
KR20120124428A (ko) 2009-12-30 2012-11-13 아르퀼 인코포레이티드 치환된 피롤로-아미노피리미딘 화합물
WO2012061342A2 (en) 2010-11-01 2012-05-10 Arqule, Inc. Substituted benzo-imidazo-pyrido-diazepine compounds
CN104321322A (zh) * 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
CN104470931B (zh) 2012-05-21 2016-10-26 拜耳医药股份有限公司 取代的苯并噻吩并嘧啶
CA2873971A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
CN104507950B (zh) 2012-05-21 2017-03-22 拜耳医药股份有限公司 噻吩并嘧啶
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CN103664993B (zh) * 2012-09-25 2016-05-25 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN105189518A (zh) 2013-02-01 2015-12-23 拜耳制药股份公司 取代的噻吩并吡啶和其药物用途
HK1220972A1 (zh) 2013-03-06 2017-05-19 Bayer Pharma Aktiengesellschaft 取代的噻唑并嘧啶
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
SG11201607990QA (en) 2014-04-25 2016-11-29 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105061461B (zh) * 2015-08-18 2017-06-30 沈阳药科大学 含有苄胺结构的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
CN105061460B (zh) * 2015-08-18 2017-06-30 沈阳药科大学 含有硫醚结构的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106243124B (zh) * 2016-07-29 2018-03-09 湖北民族学院 一种噻吩并嘧啶脲类化合物及其制备方法和应用
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN106810512B (zh) * 2017-01-18 2019-09-10 江苏省中医药研究院 Idh2突变体抑制剂及其用途
CR20200124A (es) * 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
MX2020001719A (es) * 2017-08-15 2020-11-06 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y metodos de uso.
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
US12492204B2 (en) 2019-08-26 2025-12-09 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl) amino compounds useful as JAK 1 inhibitors
CN112500421B (zh) * 2020-12-15 2021-08-24 河南科技大学第一附属医院 一种可用于杀菌消毒的苯并吡喃脲类化合物的制备方法及应用
TW202413367A (zh) * 2022-08-19 2024-04-01 財團法人國家衛生研究院 Tam受體抑制劑
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US6814324B2 (en) * 2002-07-03 2004-11-09 Segway Systems, Llc Releasably latchable leader block in tape threading apparatus for data storage systems and method therefor
UA83814C2 (ru) 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
WO2005037825A2 (en) * 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
US20050153989A1 (en) 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
KR101792651B1 (ko) 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
JP2008505167A (ja) 2004-07-05 2008-02-21 アステックス、セラピューティックス、リミテッド 医薬組成物
CN101160316A (zh) * 2004-07-16 2008-04-09 苏内西斯医药公司 适合用作aurora激酶抑制剂的噻吩并嘧啶
DE602005024274D1 (de) * 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
JP5102771B2 (ja) * 2005-10-28 2012-12-19 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼとしての化合物および組成物
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases

Also Published As

Publication number Publication date
CA2722220A1 (en) 2009-11-05
WO2009134658A3 (en) 2009-12-30
EP2276346A2 (en) 2011-01-26
EP2276346B1 (en) 2016-11-23
PL2276346T3 (pl) 2017-07-31
KR20100132067A (ko) 2010-12-16
KR101667822B1 (ko) 2016-10-19
CN102014627B (zh) 2014-10-29
HK1151694A1 (en) 2012-02-10
AU2009241469B2 (en) 2015-05-07
US20090275533A1 (en) 2009-11-05
CA2722220C (en) 2016-06-07
TW200948365A (en) 2009-12-01
JP5502072B2 (ja) 2014-05-28
TWI363627B (en) 2012-05-11
DK2276346T3 (en) 2017-02-27
EP2276346A4 (en) 2011-08-24
CN102014627A (zh) 2011-04-13
JP2011522789A (ja) 2011-08-04
US8138194B2 (en) 2012-03-20
AU2009241469A1 (en) 2009-11-05
WO2009134658A2 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
ES2515194T3 (es) Derivados de pirrolidina
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
AR066379A1 (es) Amidas de acido carboxilico su preparacion y su uso como medicamentos
AR058776A1 (es) Compuesto de piridina condensado
ECSP11011200A (es) Derivados de oxadiazale como agonista de los receptores s1p1
ES2607952T3 (es) Derivados tricíclicos de Pirazol Amina
ES2530431T3 (es) Compuestos heterocíclicos como moduladores positivos del receptor de glutamato metabotrópico 2 (receptor mGlu2)
MX2017009625A (es) Compuestos macrociclicos como inhibidores de cinasas asociadas al receptor de interleucina1/4 (irak1/4) y usos de los mismos.
CO6260132A2 (es) Derivados de oxadiazol como inhibidores de dgat
ES2571405T3 (es) Compuestos y composiciones fotocrómicos
AR076164A1 (es) Inhibidores de anillos fusionados de hepatitis c
AR052558A1 (es) Derivados de tiazol-4-carboxamida como antagonistas de mglur5
CO5611110A2 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
CO6220967A2 (es) Compuestos organicos y sus usos
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
PE20080888A1 (es) COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
PE20141586A1 (es) Compuestos de heteroaril piridona y aza-piridona como inhibidores de actividad btk
CO6160312A2 (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR078576A1 (es) Amidas y tioamidas de diazol utiles para combatir parasitos animales, en particular insectos y procedimiento para prepararlas.
AR071745A1 (es) Compuestos sacaridos unidos a heterociclos, inhibidores de polimerasas virales, composiciones farmaceuticas que los comprenden y usos de los mismos como agentes antivirales y/o anticancer.
CY1117862T1 (el) Ετεροκυκλικες ενωσεις βενζοδιοξολιου ή βενζοδιοξεπινης ως αναστολεις φωσφοδιεστερασης
ECSP088129A (es) Derivado novedoso de heterocicliden acetamida
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa